Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis

References

• Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567–1601.
   PubMed Web of Science ®Google Scholar
• Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519–531.
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531–540.
   PubMed Web of Science ®Google Scholar
• Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 2011; 54: e301–312.
   PubMed Web of Science ®Google Scholar
• Wenzel R, Del Favero A, Kibbler C, . Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55: 352–361.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Andes DR, Marr KA, . Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559–1567.
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, . The economic costs to United States hospitals of invasive fungal infections in transplant patients. Amer J Infect Control 2011; 30: e15–20.
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF, . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, . Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2–12.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, . Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227–1233.
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, . Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009; 66: 1711–1717.
   PubMed Web of Science ®Google Scholar
• Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009; 13: 24–36.
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, . Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43: S49–58.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, . Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101–1111.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091–1100.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
   PubMed Web of Science ®Google Scholar
• Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004; 56: 269–276.
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524–1528.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: e711–716.
   PubMed Web of Science ®Google Scholar